It promotes harmony among those living in harsh environments, says new study

The Economist reports that many life science companies are betting big on AI to help with drug development. Why? If AI can increase their likelihood new molecules become successful drugs, the cost of drug development will fall. AI-designed molecules show an 80-90% success rate in early-stage safety trials, compared with a historical average of just…

New York prosecutors sued the former CEO of Emergent BioSolutions over alleged insider trading while the contract manufacturer struggled with contamination issues making AstraZeneca's Covid-19 vaccine during the pandemic. The lawsuit ...

As I highlighted last week, we are entering the Net Pricing Drug Channel (NPDC) era—a market environment in which net prices, not list prices, determine access, economics, and competitive strategy. This shift represents a structural change in how value is created and captured across the U.S. drug channel. The NPDC will: * Reward simpler pricing models * Penalize rebate-heavy strategies * Expose business models built on gross-to-net arbitrage * Force channel participants to rethink how they add value when money flows more transparently through the system The short video below, excerpted from my recent Drug Channels Outlook 2026, explains why this shift is accelerating. It walks through the key forces now deflating the gross-to-net bubble and explains how manufacturers and other channel participants are responding. Can’t see the video? Click here to watch the NPDC clip. For a deeper, data-driven look at the trends, market forces, and policy developments shaping the U.S. drug channel in 2026 and beyond, watch the full webinar replay and download the complete slide deck. UPCOMING 2026 LIVE VIDEO WEBINARS The Drug Channels 2026 Video Webinar Series During 2026, DCI will be hosting three live, interactive video webinars focused on the issues that matter most as they’re happening—policy shifts, market trends, and major company moves. Click here to register. ADDITIONAL BACKGROUND AND ANALYSIS For more context on the emergence of the Net Pricing Drug Channel and the slowdown in the gross-to-net bubble’s growth, see these Drug Channels articles: * U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges * Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low * List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.        

President Donald Trump wants new legislation that cements his "most favored nation" deals with drugmakers, asking Congress to put the drug price discounts into law that the pharma industry has so far voluntarily agreed to ...

Eli Lilly and Novo Nordisk have waged a bitter legal campaign against compounding pharmacies that have churned out custom versions of their blockbuster obesity drugs over the last couple of years. Now, one is fighting ...

SAN FRANCISCO — Shanghai Fosun Pharmaceutical, a major Chinese healthcare manufacturer, aims to build itself into a global drug innovator, an executive with the company told Endpoints News at the JP Morgan Healthcare Conference. ...

Plus, news about Insmed: ? Alfasigma strikes deal for neurological disease treatment: The pharma company has secured global rights to the parenteral formulation of Innovative Molecules’ drug candidate adibelivir for Herpes ...

The FDA is set to meet with Novo Nordisk sometime early this year to discuss the progress made at its troubled Indiana facility, formerly run by Catalent. This is according to ...

Eye disease gene therapy developer Ocugen reported positive interim Phase 2 data for its geographic atrophy program from a small number of patients. Researchers were testing two different dose levels of the experimental therapy, which ...

Johnson & Johnson’s Tecvayli has achieved survival outcomes in a Phase 3 trial that bode well for its ambitions to expand its use to earlier lines of multiple myeloma. The MajesTEC-9 study enrolled patients with ...

Scribe Therapeutics, founded almost nine years ago to develop medicines based on novel CRISPR enzymes, is getting ready to test its first therapy in the clinic this summer, the gene editing startup told Endpoints News ...

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI), for three new video webinars during 2026. These live, interactive events are designed for executives who need timely insight into the rapidly changing U.S. drug channel. They will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. Register Now During these events, Dr. Fein will address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, company announcements, and more. He’ll share DCI’s latest market data to help you stay on top of new developments. You will be able to use these events as both a capstone of your current learning and a touchpoint for the future. Jump to: * Event Schedule * Pricing Options * Important Things To Know EVENT SCHEDULE The three events are scheduled for 12:00 p.m. to 1:30 p.m. ET on the following dates: * April 10, 2026 * June 12, 2026 * December 11, 2026 (Drug Channels Outlook 2027) Topics will be finalized closer to each date to reflect breaking trends, policy changes, and major company announcements—so the content stays timely, relevant, and immediately useful. PRICING OPTIONS Register for all three events for $1,080 per viewing device (or $360 per viewing device for a single event). We understand that many professionals are working remotely, so we’re offering substantial savings for multiple registrations from the same organization. What's more, an unlimited number of attendees can watch together at a single physical location with one registered device. Important Reminder: Each device at a single physical location must have its own registration. The webinars may not be recorded, streamed, broadcast, or shared across different locations, devices, or sites. Click here to register. All discounts will be automatically computed based on the number of registrations you enter in your cart. (You can reset the cart by entering 0 in the quantity field.) The Drug Channels 2026 Video Webinar Series Questions about corporate pricing? Please contact Marie Caldwell (mcaldwell@hmpglobal.com). Purchasing access for multiple sites? We'll contact you for your participant list. Or, download the 2026 Drug Channels Webinar Registration spreadsheet and submit it to dcisupport@hmpglobal.com. Payment can be made with all major credit cards (Visa, MasterCard, American Express, and Discover). Prefer check or ACH? Click here to request an invoice. IMPORTANT THINGS TO KNOW * Watch and listen via any device with a web browser (computer, iPad, iPhone/Android, etc.) There is no access via telephone. * We use Zoom technology for this webinar. Every registrant will receive an email from Zoom with a link to watch the event. This link is unique to the registrant and can only be accessed once. We recommend that every registrant downloads the Zoom client software/app. * Prior to each event, every registrant will receive an email from Zoom with a link to access the event and add it to their calendar. They will also receive reminder emails one week before and one hour before each event. * During each webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. * Can’t attend the live event? After each event, every registrant will receive an email with information on how to view a replay of the Zoom video recording. Every registrant will also be able to download a PDF of the full slide deck. * Each registration for a DCI webinar is valid for a single device at a single physical location. Each device at a physical location and the viewer(s) at that location requires its own registration. Attendees are not permitted to record, stream, share, or project a DCI webinar to other sites. Purchasers who violate this limitation by recording, streaming, sharing, or projecting a DCI webinar to other sites are liable for the full cost of all locations that viewed the webinar. DCI reserves the right to ban purchasers who violate our terms from attending future DCI webinars. * Unfortunately, we are unable to offer refunds. © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.        

AbbVie began 2025 with a T cell engager deal in China, and it's ending the year with another one. The Chicago-area pharmaceutical giant is going to Zelgen Biopharmaceuticals for a clinical-stage T cell engager called ...

Most people train too fast

Rural Emergency Hospitals (REHs) are a new Medicare provider type created to preserve essential emergency and outpatient access in rural communities where low inpatient volume makes full-service hospitals financially unsustainable. They receive enhanced outpatient payments and a fixed monthly facility payment in exchange for forgoing acute inpatient care.​ CMS has an REH fact sheet that…

Are You Stuck in the Zero-Traffic Loop?Every creator and entrepreneur faces the same painful paradox: You need traffic to grow, but you need an audience to get traffic. You're spending all your time…

The FDA approved Agios Pharmaceuticals’ drug mitapivat to treat thalassemia on Tuesday, under the name Aqvesme, following a three-month delay and a missed deadline. The approval marks a key step forward ...

Novo Nordisk has won US approval of the first oral treatment for obesity in more than a decade. The Danish drugmaker’s obesity pill was approved by the FDA on Monday. It ...

After a dormant couple of months, the biotech IPO market might crack open at the start of 2026. Aktis Oncology, a biotech in the buzzy radiopharmaceutical space, submitted its pitch for ...

Welcome back to Endpoints Weekly! Before we get into this week’s headlines, here’s a holiday programming note: We won’t be sending our Saturday newsletter on Dec. 27 or Jan. 3. Our daily newsletters will also ...